Viewing Study NCT03929666

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:42 PM
Ignite Modification Date: 2026-01-25 @ 12:02 PM
Study NCT ID: NCT03929666
Status: COMPLETED
Last Update Posted: 2025-09-12
First Post: 2019-02-22
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Sponsor: Jazz Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and … View
Keywords:

Keywords

Keyword Brief Keyword Text View
None HER2 View
None Bispecific antibody View
None Biparatopic antibody View
None Immunotherapy View
None Gastric cancers View
None Esophageal cancers View
None Gastroesophageal junction (GEJ) cancers View
None Chemotherapy View
None FP View
None mFOLFOX6 View
None Capecitabine View
None Cisplatin View
None 5-FU View
None Leucovorin (folinic acid) View
None Oxaliplatin View
None XELOX View
None Gastrointestinal cancers View
None Gastroesophageal adenocarcinoma View
None Biliary tract cancer View
None Colorectal cancer View
None Intrahepatic cholangiocarcinoma View
None Extrahepatic cholangiocarcinoma View
None Gall bladder View